Nature Cancer

Article	Citations
Cancer vaccines: the next immunotherapy frontier	344
Overcoming therapy resistance in EGFR-mutant lung cancer	245
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	237
Cancer-associated fibroblasts in the single-cell era	225
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	203
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	202
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	197
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	191
Fatty acid synthesis is required for breast cancer brain metastasis	186
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	186
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	178
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	178
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	178
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	167
The metabolic landscape of RAS-driven cancers from biology to therapy	163
The cGAS–STING pathway and cancer	158
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	147
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	144
CD4+ T cells in cancer	138
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	135
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	134
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	134
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	132
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	130
Translational advances in pancreatic ductal adenocarcinoma therapy	130

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	127
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	125
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	116
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	115
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	113
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	113
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	110
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	109
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	106
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	104
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	104
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	103
Targeting public neoantigens for cancer immunotherapy	100
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	98
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	95
Emerging strategies for treating metastasis	94
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	93
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	93
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	90
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	88
Cancer cell plasticity during tumor progression, metastasis and response to therapy	87
The present and future of PI3K inhibitors for cancer therapy	82
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	82
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	82
Dysregulation and therapeutic targeting of RNA splicing in cancer	81
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	81
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	81
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	80
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	79
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	79
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	78
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	76
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	76
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	75
Engineering-enhanced CAR T cells for improved cancer therapy	74
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	72
Bystander T cells in cancer immunology and therapy	71
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	70
The status of tumor mutational burden and immunotherapy	70
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	69
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	68
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	68
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	66
Advances in antibody-based therapy in oncology	65
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	65
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	65
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	64
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	64
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	61
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	61

Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	60
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	60
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	60
Clinical and translational advances in ovarian cancer therapy	60
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	59
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	59
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	59
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	59
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	59
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	57
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	57
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer	56
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	55
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	54
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms	54
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	54
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	53
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	52
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	52
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	52
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming	51
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	51
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	51
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	51
ALK-positive lung cancer: a moving target	50
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	50
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance	50
Accelerating precision medicine in metastatic prostate cancer	50
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling	50
Advancing Cancer Therapy	49
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	49
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	49
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis	48
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription	48
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	48
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors	47
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer	47
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	47
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	47
Moving pan-cancer studies from basic research toward the clinic	46
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis	46
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations	45
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade	44
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers	43
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	43
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	42
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice	42
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	42
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors	41
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1	41
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth	41
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress	40
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	39
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer	38
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	38
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	38
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	38
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	38
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	37
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	36
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	36
Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response	36
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia	36
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	35
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity	35
LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis	35
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	35
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	35
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries	35
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	35
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer	34
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer	34
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	33
The landscape of T cell antigens for cancer immunotherapy	33
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	33
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse	32
The current landscape of immunotherapy for pediatric brain tumors	32
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis	31
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	31
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer	31

The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer	31
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	31
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma	30
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer	30
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	30
Advances in ovarian cancer, from biology to treatment	30
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	29
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	29
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	29
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	29
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy	29
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	29
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy	28
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS	28
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells	28
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer	28
Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis	27
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	27
Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse	27
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	27
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations	27
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	26
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity	26
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation	26
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	26
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	25
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer	25
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44	25
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer	25
Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade	24
Charting roadmaps towards novel and safe synergistic immunotherapy combinations	24
Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers	24
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches	24
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis	24
Missing the target in cancer therapy	23
LAG-3 and PD-1 blockade raises the bar for melanoma	23
Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2	23
Acute lymphoblastic leukemia displays a distinct highly methylated genome	23
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy	23
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	23
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	22
Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism	22
γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors	21
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer	21
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors	21
Starfish infers signatures of complex genomic rearrangements across human cancers	20
Inferring early genetic progression in cancers with unobtainable premalignant disease	20
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells	20
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	20
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology	20
Apoptosis-induced nuclear expulsion in tumor cells drives S100a4-mediated metastatic outgrowth through the RAGE pathway	20
Envisioning the future of precision oncology trials	20
Eliminating cervical cancer in the COVID-19 era	20
Non-lethal outcomes of engaging regulated cell death pathways in cancer	19
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	19
FYN–TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma	19
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2	19
Future directions in preclinical and translational cancer neuroscience research	19
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment	19
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	19
Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes	19
NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation	18
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer	18
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism	18
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	18
The pleiotropic functions of reactive oxygen species in cancer	18
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias	17
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer	17
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC	17
Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity	17
Lipids as mediators of cancer progression and metastasis	17
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	17
Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases	16
The next generation of DNMT inhibitors	16
Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity	16
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	16
Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma	16
Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47	16
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial	15
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer	15
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	15
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	15
KRAS inhibitors, approved	15
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction	15
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells	15
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	14
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	14
A decade of CAR T cell evolution	14
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity	14
Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy	14
Impact of context-dependent autophagy states on tumor progression	14
Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma	13
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers	13
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	13
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma	13